Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review

Detalhes bibliográficos
Autor(a) principal: Paiva, Edson Bruno Campos
Data de Publicação: 2022
Outros Autores: Silveira, Caroline Rocha da, Kosmiscky, Isis de Oliveira, Gomes , Cleiton da Costa, Barros, Samantha Daniely Gomes, Farias, Roselígia Antônia da Costa, Saldanha, Zélia de Oliveira, Gomes, Antônio Rafael Quadros, Coelho, Cybelle Silva do Couto, Cartágenes, Sabrina de Carvalho
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/24710
Resumo: This article is a narrative review of the literature which aims to describe the main pharmacological aspects of pre-exposure prophylaxis (PrEP) to HIV. The human immunodeficiency virus (HIV) is an infection that has affected people all over the world. However, this number has decreased in recent decades, this is due to the demand for information leading to prevention and adherence to the use of PrEP PrEP is characterized as a prevention strategy that includes the daily and continuous use of antiretroviral drugs, studies show the effectiveness of the combined use of two daily antiretroviral drugs, tenofovir (TDF) and emtricitabine, commercially known as truvada. However, it is extremely important to know and discuss the pharmacological aspects of the drug, and this involves its pharmacokinetics, which in turn includes the mechanisms of absorption, distribution, metabolism and excretion of the drug, as well as other important parameters such as the half-life and elimination time of the drug, and its possible drug interactions, adverse reactions, and its mechanism of action, which is associated with the pharmacodynamic aspects of the drug.
id UNIFEI_3c50fdb02230550fb0c9a9165faef313
oai_identifier_str oai:ojs.pkp.sfu.ca:article/24710
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a reviewAspectos farmacológicos de la profilaxis previa a la exposición (prep) al VIH: una revisiónAspectos farmacológicos da profilaxia de pré-exposição (prep) ao HIV: revisãoPharmacological aspectsHIVPre-exposure prophylaxisPrEP.Aspectos farmacológicosVIHProfilaxis previa a la exposiciónPrEP.Aspectos farmacológicosHIVProfilaxia pré-exposiçãoPrEP.This article is a narrative review of the literature which aims to describe the main pharmacological aspects of pre-exposure prophylaxis (PrEP) to HIV. The human immunodeficiency virus (HIV) is an infection that has affected people all over the world. However, this number has decreased in recent decades, this is due to the demand for information leading to prevention and adherence to the use of PrEP PrEP is characterized as a prevention strategy that includes the daily and continuous use of antiretroviral drugs, studies show the effectiveness of the combined use of two daily antiretroviral drugs, tenofovir (TDF) and emtricitabine, commercially known as truvada. However, it is extremely important to know and discuss the pharmacological aspects of the drug, and this involves its pharmacokinetics, which in turn includes the mechanisms of absorption, distribution, metabolism and excretion of the drug, as well as other important parameters such as the half-life and elimination time of the drug, and its possible drug interactions, adverse reactions, and its mechanism of action, which is associated with the pharmacodynamic aspects of the drug.Este artículo es el resultado de una revisión bibliográfica narrativa que pretende describir los principales aspectos farmacológicos de la profilaxis preexposición (PPrE) al VIH. El virus de la inmunodeficiencia humana (VIH), es una infección que ha afectado a personas de todo el mundo. Sin embargo, este número ha disminuido en las últimas décadas, esto se debe a la demanda de información que lleva a la prevención y a la adherencia al uso de la PrEP La PrEP se caracteriza por ser una estrategia de prevención que incluye el uso diario y continuo de medicamentos antirretrovirales, los estudios demuestran la eficacia del uso combinado de dos medicamentos antirretrovirales diarios, tenofovir (TDF) y emtricitabina, conocido comercialmente como truvada. Sin embargo, es sumamente importante conocer y discutir los aspectos farmacológicos del fármaco y esto implica su farmacocinética, que a su vez incluye los mecanismos de absorción, distribución, metabolismo y excreción del fármaco, así como otros parámetros importantes como la vida media y el tiempo de eliminación del fármaco, así como sus posibles interacciones farmacológicas, reacciones adversas y su mecanismo de acción, que se asocia con los aspectos farmacodinámicos del fármaco.Este artigo é uma revisão narrativa da literatura que visa descrever os principais aspectos farmacológicos da profilaxia pré-exposição (PrEP) ao VIH. O vírus da imunodeficiência humana (VIH) é uma infecção que tem afetado pessoas em todo o mundo. Contudo, este número diminuiu nas últimas décadas, isto deve-se à procura de informação conducente à prevenção e à adesão ao uso da PrEP PrEP caracteriza-se como uma estratégia de prevenção que inclui o uso diário e contínuo de medicamentos antirretrovirais, estudos mostram a eficácia do uso combinado de dois medicamentos antirretrovirais diários, tenofovir (TDF) e emtricitabina, comercialmente conhecido como truvada. No entanto, é extremamente importante conhecer e discutir os aspectos farmacológicos do fármaco, e isto envolve a sua farmacocinética, que por sua vez inclui os mecanismos de absorção, distribuição, metabolismo e excreção do fármaco, bem como outros parâmetros importantes como o tempo de meia-vida e eliminação do fármaco, e as suas possíveis interações medicamentosas, reações adversas, e o seu mecanismo de ação, que está associado com os aspectos farmacodinâmicos do fármaco.Research, Society and Development2022-07-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2471010.33448/rsd-v11i9.24710Research, Society and Development; Vol. 11 No. 9; e15511924710Research, Society and Development; Vol. 11 Núm. 9; e15511924710Research, Society and Development; v. 11 n. 9; e155119247102525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/24710/27011Copyright (c) 2022 Edson Bruno Campos Paiva; Caroline Rocha da Silveira; Isis de Oliveira Kosmiscky; Cleiton da Costa Gomes ; Samantha Daniely Gomes Barros; Roselígia Antônia da Costa Farias; Zélia de Oliveira Saldanha; Antônio Rafael Quadros Gomes; Cybelle Silva do Couto Coelho; Sabrina de Carvalho Cartágeneshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessPaiva, Edson Bruno Campos Silveira, Caroline Rocha da Kosmiscky, Isis de Oliveira Gomes , Cleiton da CostaBarros, Samantha Daniely Gomes Farias, Roselígia Antônia da Costa Saldanha, Zélia de Oliveira Gomes, Antônio Rafael Quadros Coelho, Cybelle Silva do Couto Cartágenes, Sabrina de Carvalho2022-07-21T12:36:16Zoai:ojs.pkp.sfu.ca:article/24710Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:43:10.753011Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review
Aspectos farmacológicos de la profilaxis previa a la exposición (prep) al VIH: una revisión
Aspectos farmacológicos da profilaxia de pré-exposição (prep) ao HIV: revisão
title Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review
spellingShingle Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review
Paiva, Edson Bruno Campos
Pharmacological aspects
HIV
Pre-exposure prophylaxis
PrEP.
Aspectos farmacológicos
VIH
Profilaxis previa a la exposición
PrEP.
Aspectos farmacológicos
HIV
Profilaxia pré-exposição
PrEP.
title_short Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review
title_full Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review
title_fullStr Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review
title_full_unstemmed Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review
title_sort Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review
author Paiva, Edson Bruno Campos
author_facet Paiva, Edson Bruno Campos
Silveira, Caroline Rocha da
Kosmiscky, Isis de Oliveira
Gomes , Cleiton da Costa
Barros, Samantha Daniely Gomes
Farias, Roselígia Antônia da Costa
Saldanha, Zélia de Oliveira
Gomes, Antônio Rafael Quadros
Coelho, Cybelle Silva do Couto
Cartágenes, Sabrina de Carvalho
author_role author
author2 Silveira, Caroline Rocha da
Kosmiscky, Isis de Oliveira
Gomes , Cleiton da Costa
Barros, Samantha Daniely Gomes
Farias, Roselígia Antônia da Costa
Saldanha, Zélia de Oliveira
Gomes, Antônio Rafael Quadros
Coelho, Cybelle Silva do Couto
Cartágenes, Sabrina de Carvalho
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Paiva, Edson Bruno Campos
Silveira, Caroline Rocha da
Kosmiscky, Isis de Oliveira
Gomes , Cleiton da Costa
Barros, Samantha Daniely Gomes
Farias, Roselígia Antônia da Costa
Saldanha, Zélia de Oliveira
Gomes, Antônio Rafael Quadros
Coelho, Cybelle Silva do Couto
Cartágenes, Sabrina de Carvalho
dc.subject.por.fl_str_mv Pharmacological aspects
HIV
Pre-exposure prophylaxis
PrEP.
Aspectos farmacológicos
VIH
Profilaxis previa a la exposición
PrEP.
Aspectos farmacológicos
HIV
Profilaxia pré-exposição
PrEP.
topic Pharmacological aspects
HIV
Pre-exposure prophylaxis
PrEP.
Aspectos farmacológicos
VIH
Profilaxis previa a la exposición
PrEP.
Aspectos farmacológicos
HIV
Profilaxia pré-exposição
PrEP.
description This article is a narrative review of the literature which aims to describe the main pharmacological aspects of pre-exposure prophylaxis (PrEP) to HIV. The human immunodeficiency virus (HIV) is an infection that has affected people all over the world. However, this number has decreased in recent decades, this is due to the demand for information leading to prevention and adherence to the use of PrEP PrEP is characterized as a prevention strategy that includes the daily and continuous use of antiretroviral drugs, studies show the effectiveness of the combined use of two daily antiretroviral drugs, tenofovir (TDF) and emtricitabine, commercially known as truvada. However, it is extremely important to know and discuss the pharmacological aspects of the drug, and this involves its pharmacokinetics, which in turn includes the mechanisms of absorption, distribution, metabolism and excretion of the drug, as well as other important parameters such as the half-life and elimination time of the drug, and its possible drug interactions, adverse reactions, and its mechanism of action, which is associated with the pharmacodynamic aspects of the drug.
publishDate 2022
dc.date.none.fl_str_mv 2022-07-05
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/24710
10.33448/rsd-v11i9.24710
url https://rsdjournal.org/index.php/rsd/article/view/24710
identifier_str_mv 10.33448/rsd-v11i9.24710
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/24710/27011
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 9; e15511924710
Research, Society and Development; Vol. 11 Núm. 9; e15511924710
Research, Society and Development; v. 11 n. 9; e15511924710
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052791829561344